
|Videos|December 29, 2021
Dr. Morgans highlights research and advancements from SUO 2021
Author(s)Urology Times staff
“Imaging advances with PSMA-directed modalities…are absolutely shifting the landscape,” says Alicia K. Morgans, MD, MPH.
Advertisement
In this video, Alicia K. Morgans, MD, MPH, discusses highlights of the recent 2021 Society of Urologic Oncology Annual Meeting. Morgans is a genitourinary medical oncologist and medical director of the Survivorship Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












